Drug
131 I Omburtamab
131 I Omburtamab: highest development phase Phase 2, developed by Y-mAbs Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Y-mAbs Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| 131 I-omburtamab NCT04022213 | Phase 2 | Desmoplastic Small Round Cell Tumor |
Latest
No recent events.
Follow 131 I Omburtamab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.